维格列汀联合胰岛素治疗对肥胖型2型糖尿病患者HbA1c、vaspin水平及胰岛β细胞功能的影响

Effects of Vildagliptin Combined with Insulin on HbA1c and Vaspin Levels and Isletβ-cell Function in Obese Type 2 Diabetes Mellitus

目的:探讨维格列汀联合胰岛素治疗对肥胖型2型糖尿病(T2DM)患者血糖和胰岛β细胞功能的影响。方法:选取2018年3月-2020年3月本院收治的86例肥胖T2DM患者。按随机数字表法分为对照组和观察组,各43例。对照组予以胰岛素治疗,观察组在对照组基础上加用维格列汀治疗。比较两组血糖相关指标水平、胰岛β细胞功能(HOMA-β)、丝氨酸蛋白酶抑制剂(vaspin),并观察两组不良反应发生情况。结果:治疗12周后,观察组空腹血糖(FPG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PG)水平均低于对照组,差异均有统计学意义(P<0.05)。治疗12周后,观察组vaspin、HOMA-β均高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:维格列汀联合胰岛素治疗可稳定控制肥胖T2DM患者血糖水平,增强胰岛β细胞功能,且不增加不良反应。

Objective:To investigate the effects of Vildagliptin combined with Insulin on blood glucose and isletβ-cell function in patients with obese type 2 diabetes mellitus(T2DM).Method:A total of 86 obese T2DM patients admitted to our hospital from March 2018 to March 2020 were selected.According to random number table method,they were divided into control group and observation group,43 cases in each group.The control group was treated with Insulin,and the observation group was additively treated with Vildagliptin.Blood glucose related indexes,isletβcell function(HOMA-β),serine protease inhibitor(vaspin)were compared between two groups,the incidence of adverse reactions in two groups were observed.Result:At 12 weeks after treatment,the levels of fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c)and 2 h postprandial plasma glucose(2 h PG)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).At 12 weeks after treatment,vaspin and HOMA-βin the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Vildagliptin combined with Insulin can stably control the blood glucose level in obese T2DM patients and enhance the function of isletβ-cell without increasing the adverse reactions.